Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus adjuvant cisplatin-based radiochemotherapy versus adjuvant cisplatin-based radiochemotherapy in resected locally advanced head and neck squamous cell carcinoma
2017-002546-74Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Mar 2018
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Adjuvant radiochemotherapy with cisplatin with Adjuvant radiochemotherapy with cisplatin and pembrolizumab (2 arms). Primary endpoint: Event-free survival. Started Mar 2018; status: completed.
02
Drugs
pembrolizumabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-002546-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002546-74.